Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Cardio protective molecule against chemotherapy induced heart failure

FY 2015-16

Summary
Treatment with chemotherapy and antineoplastic drugs is associated with cardiotoxicity and damage of the cardiac muscle that lead to heart failure. Identification of cardioprotective drugs that can be given during cancer treatment without affecting its efficacy is the ultimate approach to prevent heart damage in cancer survivors. The Nemer laboratory identified GATA4 as a master regulator of cardiomyocytes' survival and has recently designed a new cardioprotective molecule CPM-2122. Preliminary data both in vitro and in vivo showed that CPM-2122 prevented anthracycline-induced cardiomyocyte death and preserved cardiac function. The objectives of my Masters project will be to study the mechanism of action of CPM-2122 in cardiomyocytes, to check if CPM-2122 is cardioprotective against other anti-cancer drugs and to assess the effect of CPM-2122 on the efficacy of anti-cancer treatment. Gene expression profile and survival signaling effects will be checked in primary neonatal cardiomyocytes treated with CPM-2122 as well as its direct cardioprotective role with different anti-cancer drug treatments. The effect of CPM-2122 on the efficacy of anti-cancer treatment will be evaluated using human cancer cell lines. Xenograft mouse models will be used to verify the results in vivo. This work will help validate CPM-2122 as a cardioprotective drug to be used during anti-cancer treatments for the prevention of heart failure.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349902
Name
Collins Laura N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cardio protective molecule against chemotherapy induced heart failure
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anthracycline; Antineoplastic; Cardiomyocyte; Cardioprotection; Cardiotoxicity; Chemotherapy; Gene Expression; Heart Failure; Mechanism; Survival Signaling
Abstract
Treatment with chemotherapy and antineoplastic drugs is associated with cardiotoxicity and damage of the cardiac muscle that lead to heart failure. Identification of cardioprotective drugs that can be given during cancer treatment without affecting its efficacy is the ultimate approach to prevent heart damage in cancer survivors. The Nemer laboratory identified GATA4 as a master regulator of cardiomyocytes' survival and has recently designed a new cardioprotective molecule CPM-2122. Preliminary data both in vitro and in vivo showed that CPM-2122 prevented anthracycline-induced cardiomyocyte death and preserved cardiac function. The objectives of my Masters project will be to study the mechanism of action of CPM-2122 in cardiomyocytes, to check if CPM-2122 is cardioprotective against other anti-cancer drugs and to assess the effect of CPM-2122 on the efficacy of anti-cancer treatment. Gene expression profile and survival signaling effects will be checked in primary neonatal cardiomyocytes treated with CPM-2122 as well as its direct cardioprotective role with different anti-cancer drug treatments. The effect of CPM-2122 on the efficacy of anti-cancer treatment will be evaluated using human cancer cell lines. Xenograft mouse models will be used to verify the results in vivo. This work will help validate CPM-2122 as a cardioprotective drug to be used during anti-cancer treatments for the prevention of heart failure.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Collins, Laura N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~